Celebrating our Journey of Hope! Join us as we usher in PWSA | USA’s 50th Anniversary. Learn More

PWSA Blog

Free Live Webinar: Understanding VYKAT XR – The First FDA-Approved Treatment for Hyperphagia in PWS

Date: Wednesday, April 16, 2025
Time: 9:15 AM PT | 12:15 PM ET
Location: Virtual via ZOOM

The Prader-Willi syndrome (PWS) community has reached a historic milestone – VYKAT XR (formerly known as DCCR in clinical trials) is now FDA-approved as the first-ever treatment for hyperphagia in PWS. To help families, caregivers, and healthcare providers understand what this means, Soleno Therapeutics and Medlive, in partnership with PWSA | USA and FPWR, are hosting a free, live webinar featuring expert speakers, real-life caregiver experiences, and important information about VYKAT XR.

What You’ll Learn

– How to recognize hyperphagia in people living with PWS
– How VYKAT XR works to manage hyperphagia
– A caregiver’s personal experience with VYKAT XR
– How to get started with VYKAT XR

Featured Speakers

Kathryn Obrynba, MD – Nationwide Children’s Hospital
Deahl Wilson – Caring for a loved one with PWS
Stacy Ward – CEO, Prader-Willi Syndrome Association | USA
Susan Hedstrom – Executive Director, Foundation for Prader-Willi Research
Brennen Fields – Senior Director, Patient Access Solutions, Soleno Therapeutics

VYKAT XR’s FDA approval on March 26, 2025, marks a significant step forward in addressing one of the most challenging symptoms of PWS. This webinar is your opportunity to gain valuable insights, ask questions, and hear directly from experts and caregivers about what this treatment means for individuals with PWS and their families.

Register Today!

Don’t miss out – sign up now to secure your spot. If you are unable to attend the live session, a recording will be available.

You can also download a flyer at the button below and share it with your community to help spread the word.

Share this!

Scroll to top